AV-380 (anti-GDF15 IgG1 mAb)

AV-380 is AVEO’s first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro-inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia. Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It is estimated that cachexia affects some 9 million individuals in North America, Europe and Japan1.

1 Von Haehling, et al. Cachexia as a major underestimated and unmet medical need: facts and numbers, J Cachexia. Sarcopenia Muscle. 2010 Sep; 1(1): 1-5

AV-380 is an investigational drug and has not yet been approved by the U.S. Food and Drug Administration (FDA)